Chapter 3. Management of Latent Tuberculosis in Pregnant Women with HIV Infection

$39.50

Jenna D. Theroux¹,², Hudson O. West¹, Hayley W. Hamilton¹, and Adriane B. Marino¹
¹Wingate University School of Pharmacy, Wingate University, Wingate, NC, US
²Eastowne Family Physicians, Charlotte, NC, US

Part of the book: Advances in Health and Disease. Volume 63

Abstract

Every year, approximately 10 million people develop active tuberculosis (TB) worldwide and about 1.6 million people die as a result of the infection. TB is the leading infectious disease cause of death globally. The causative agent of TB is Mycobacterium tuberculosis. Not all people infected with Mycobacterium tuberculosis develop active TB. The immunocompromised or persons with additional risk factors are at a much greater risk of developing active TB after being infected with latent tuberculosis infection (LTBI). A common cause of immunosuppression is HIV infection, especially in developing countries. According to the World Health Organization (WHO), people infected with HIV are 50 times more likely to progress to active TB than those who are not [1]. The WHO recommends using isoniazid (INH) monotherapy for patients with HIV to prevent TB infection. However, this recommendation lacks robust data for use in childbearing women. This chapter will review the use of INH for the prevention of TB in pregnant women who are also infected with HIV, focusing on the safety and efficacy of INH for the mother and fetus.


References


[1] World Health Organization. 2018. “Latent tuberculosis infection: updated and
consolidated guidelines for programmatic management.”
https://www.who.int/publications/i/item/9789241550239.
[2] National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division
of Tuberculosis Elimination Centers for Disease Control and Prevention. 2019.
“Epidemiology of Tuberculosis.” https://www.cdc.gov/tb/education/ssmodules/pdfs/module2.pdf.
[3] Nardell, Edward A. 2022. “Tuberculosis (TB).” Merck Manual. Last modified
September 2022.
https://www.merckmanuals.com/professional/infectious-diseases/mycobacteria/tuberculosis-tb.
[4] Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis,
STD, and TB Prevention, Centers for Disease Control and Prevention. 2012.
“Tuberculosis and Pregnancy Fact sheet.” Last reviewed September 1, 2012.
https://www.cdc.gov/tb/publications/factsheets/specpop/pregnancy.htm.
[5] Miele, Kathryn, Sapna Bamrah Morris, and Naomi K. Tepper. 2020. “Tuberculosis
in Pregnancy.” Obstetrics and gynecology, 135(6), 1444–1453.
DOI: https://doi.org/10.1097/AOG.0000000000003890.
[6] Thakarar, Kinna, Jake R. Morgan, Jessie M. Gaeta, Carole Hohl, Mari-Lynn
Drainoni. 2016. “Homelessness, HIV, and Incomplete Viral Suppression.” Journal
of Health Care for the Poor and Underserved. 27(1):145-156.
DOI: 10.1353/hpu.2016.0020.
[7] Lewinsohn David M., Michael K. Leonard, Philip A. LoBue, David L. Cohn,
Charles L. Daley, Ed Desmond, Joseph Keane, Deborah A Lewinsohn, Ann M
Loeffler, Gerald H Mazurek, Richard J O’Brien, Madhukar Pai, Luca Richeldi, Max
Salfinger, Thomas M Shinnick, Timothy R Sterling, David M Warshauer, Gail L
Woods 2016. “Official American Thoracic Society/Infectious Diseases Society of
America/ Centers for Disease Control and Prevention Clinical Practice Guidelines:
Diagnosis of Tuberculosis in Adults and Children.” Clinical Infectious Diseases vol
64, iss 2, e1-e33. DOI: https://doi.org/10.1093/cid/ciw694.
[8] Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis,
STD, and TB Prevention, Centers for Disease Control and Prevention. 2016.
“Interferon-Gamma Release Assays (IGRAs)- Blood Test for TB Infection.” Last
reviewed May 4, 2016. https://www.cdc.gov/tb/publications/factsheets/testing/igra.htm.
[9] Weinberg, Adriana, Lisa Aaron, Grace Montepiedra, Timothy R. Sterling, Renee
Browning, Blandina Mmbaga, Tichaona Vhembo et al. 2021. “Effects of Pregnancy
and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon
Gamma Response Assays in Women With HIV.” Clinical Infectious Diseases.
73(9):e3555-e3562. DOI: 10.1093/cid/ciaa1083.
[10] Pennsylvania Department of Health. 2019. “Nucleic Acid Amplification Testing (NAAT).” https://www.health.pa.gov/topics/Documents/Diseases%20and%20Conditions/TB/TB%20Insights_NAAT_FINAL_07.26.19.pdf.
[11] Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis,
STD, and TB Prevention, Centers for Disease Control and Prevention. 2016.
“Diagnosis of Tuberculosis Disease Fact Sheet.” Last reviewed May 4, 2016.
https://www.cdc.gov/tb/publications/factsheets/testing/diagnosis.htm.
[12] Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis,
STD, and TB Prevention, Centers for Disease Control and Prevention. 2012. “Report
of and Expert Consultation on the Uses of Nucleic Acid Amplification Tests for the
Diagnosis of Tuberculosis.” Last reviewed September 1, 2012.
https://www.cdc.gov/tb/publications/guidelines/amplification_tests/considerations.htm#:~:text=NAA%20tests%20have%20limitations%2C%20and,have%20negative%20NAA%20test%20results.
[13] Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., Menzies,
D., Horsburgh, C. R., Crane, C. M., Burgos, M., LoBue, P., Winston, C. A., &
Belknap, R. 2020. “Guidelines for the Treatment of Latent Tuberculosis Infection:
Recommendations from the National Tuberculosis Controllers Association and
CDC 2020.” Centers for Disease Control and Prevention 69(1);1–11. DOI:
http://dx.doi.org/10.15585/mmwr.rr6901a1external icon.
[14] Priftin [package insert]. Bridgewater, NJ: sanofi-aventis U.S., LLC; 2010.
[15] Pariente, Gali, Tom Leibson, Alexandra Carls, Thomasin Adams-Webber, Shinya
Ito, Gideon Koren. 2016. “Pregnancy-Associated Changes in Pharmacokinetics:
A Systematic Review.” Public Library of Science Medicine. 13(11):e1002160.
DOI: 10.1371/journal.pmed.1002160.
[16] Rifadin [package insert]. Bridgewater, NJ: sanofi-aventis U.S., LLC; 2010.
[17] Isoniazid [package insert]. Laurelton, NY: Epic Pharma, LLC; 2016.
[18] Brooks, K. M., George, J. M., Pau, A. K., Rupert, A., Mehaffy, C., De, P., Dobos,
K. M., Kellogg, A., McLaughlin, M., McManus, M., Alfaro, R. M., Hadigan, C.,
Kovacs, J. A., & Kumar, P. 2018. “Cytokine-Mediated Systemic Adverse Drug
Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly
Isoniazid and Rifapentine.” Clinical infectious diseases: an official publication of
the Infectious Diseases Society of America vol. 67,2: 193-201.
DOI: 10.1093/cid/ciy082.
[19] Swindells, Susan, Ritesh Ramchandani, Amita Gupta, Constance A. Benson, Jorge
Leon-Cruz, Noluthando Mwelase, Marc A. Jean Juste, Javier R. Lama, Javier
Valencia, Ayotunde Omoz-Oarhe, Khuanchai Supparatpinyo, Gaerolwe Masheto
2019. “One Month of Rifapentine plus Isoniazid to Prevent HIV-Related
Tuberculosis.” New England Journal of Medicine; 380:1001-1011.
DOI: 10.1056/NEJMoa1806808.
[20] Gupta, A., Montepiedra, G., Aaron, L., Theron, G., McCarthy, K., Bradford, S.,
Chipato, T., Vhembo, T., Stranix-Chibanda, L., Onyango-Makumbi, C., Masheto,
G. R., Violari, A., Mmbaga, B. T., Aurpibul, L., Bhosale, R., Mave, V., Rouzier, V.,
Hesseling, A., Shin, K., … Weinberg, A. 2017. “Isoniazid Preventive Therapy in
HIV-Infected Pregnant and Postpartum Women.” New England Journal of Medicine
381:1333-1346. DOI: 10.1056/NEJMoa1813060.
[21] Moro, R. N., Scott, N. A., Vernon, A., Tepper, N. K., Goldberg, S. V., Schwartzman,
K., Leung, C.-C., Schluger, N. W., Belknap, R. W., Chaisson, R. E., Narita, M.,
Machado, E. S., Lopez, M., Sanchez, J., Villarino, M. E., & Sterling, T. R. 2018.
“Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB
and the iAdhere Trials.” Annals of the American Thoracic Society vol. 15,5: 570-
580. DOI: 10.1513/AnnalsATS.201704-326OC.
[22] Mathad, Jyoti M., Rada Savic, Paula Britto, Priya Jayachandran, Lubbe Wiesner,
Grace Montepiedra, Jennifer Norman, Nan Zhang, Ellen Townley, Nahida
Chakhtoura, Sarah Bradford, Sandesh Patil, Stephanie Popson, Tsungai Chipato,
Vanessa Rouzier, Deborah Langat, Amphan Chalermchockcharoentkit, Portia
Kamthunzi, Amita Gupta, and Kelly E. Dooley 2021. “Pharmacokinetics and Safety
of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in
Pregnant Women.” Clinical infectious diseases: an official publication of the
Infectious Diseases Society of America vol. 74,9: 1604-1613.
DOI: 10.1093/cid/ciab665.

Category:

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!

See some of our Authors and Editors